Mary Crowley Cancer Research Center Press Release December 5, 2016
Mary Crowley Advances New Targeted Investigational Therapy for Ewing Sarcoma
For more information on Ewing Type I Clinical Trial Click Here
Three years ago, the Rutledge Foundation initiated funding to develop a new drug that targets the gene that causes Ewing sarcoma. In early October, on the Monday after the Hearts of Gold Luncheon, the first patient began treatment in the Phase I Trial of Mary Crowley Cancer Research Center’s Targeted Therapy for Type I Ewing’s. If proven effective, this could be the first drug specifically developed to treat Type I Ewing sarcoma. More patients are scheduled to enroll in 2017.
Development of the Type II Ewing therapy is currently underway, and when completed, will be ready for patient enrollment as early as 2018. The Rutledge Foundation has been privileged to donate $240,000 in 2016 to support the Type II Ewing drug, thanks in large part to the generous communities of Sam Day and Lilli Curry, in their loving memory.
This project would not be possible without the philanthropic support of private foundations like the Rutledge Foundation and families of Ewing’s patients, who understand the value of funding pediatric research. We are grateful for their support and excited about the possibilities of these new therapies. Ellen Dearman, VP Development Mary Crowley
The Ewing sarcoma Vaccine trial called VIGIL is now in Phase II/III in 9 centers around the country. Three more centers will be added in early 2018. If proven successful, VIGIL could become part of frontline treatment protocol for Ewing patients. The targeted drug, paired with the vaccine therapy, would provide the “one-two punch” that could eradicate Ewing sarcoma and reduce or eliminate highly toxic chemotherapies, radiation and radical surgeries that are currently recommended.
In addition to these two very important projects, on-going collaboration is taking place between researchers at UNT Health Science Center, Mary Crowley and Texas Children’s Hospital in Houston, to continue to improve the delivery mechanisms for cancer drugs, further reducing toxicities. We are grateful for their continued research and efforts.